Thoratec HeartMate Receives Long-Awaited Destination Therapy Indication

Thoratec will target major transplant and open-heart surgery centers in a new marketing initiative to promote the HeartMate SNAP-VE left ventricular assist device as a destination, "alternative-to-transplant" therapy for end-stage heart failure. FDA approved a PMA supplement for the indication on Nov. 6